The global biologics market size was valued at USD 611.17 billion in 2025 and is projected to grow from USD 672.29 billion in 2026 to USD 1441.11 billion by 2034, registering a CAGR of 10% during the forecast period from 2026 to 2034. North America dominated the biologics market with a market share of 43% in 2025.
Biologics are medical products derived from living organisms or biological sources and are used to prevent, treat, or manage various diseases. They include vaccines, antibodies, cell and gene therapies, and recombinant proteins. The market is driven by the growing prevalence of chronic diseases, advancements in biotechnology, increasing demand for targeted therapies, and rising investment in biopharmaceutical research and development.
Download a Free Sample To learn more about this report,
Expansion of Antibody–Drug Conjugates and Other Bioconjugates
The biologics market analysis indicates that advances in linker chemistry, payload design, and antibody engineering are expanding antibody–drug conjugates (ADCs) as a way to deliver potent therapies more selectively to target cells; 13 ADCs had received FDA approval by June 2025, targeting 11 different antigens with seven distinct cytotoxic payloads.
Development of Long-Acting Biologic Formulations
Demand for less frequent dosing and improved treatment convenience is also driving the development of long-acting biologic formulations, with half-life extension and Fc engineering helping maintain therapeutic exposure for longer periods; in 2025, the FDA approved two half-life-extended antibody products among its new antibody-based biologics.
Demand for Personalized Biologic Therapies and Investment in Biologic Drug Development Drive Market
The increasing demand for personalized biologic therapies is expanding the need for biologics tailored to specific patient and disease characteristics. Greater use of biomarker testing and patient stratification supports treatment selection based on individual biological profiles, increasing demand for specialized therapies. For example, biomarker testing can help identify cancer patients who may benefit from a specific monoclonal antibody therapy. Higher demand for targeted treatment options encourages pharmaceutical companies to expand biologic development and manufacturing capabilities. This shift toward individualized care therefore supports growth in the biologics market.
The rising investment in biologic drug development is expanding the supply pipeline by supporting research, clinical trials, and manufacturing capabilities for new biologic therapies. Higher funding from pharmaceutical companies and biotechnology firms increases the number of biologic candidates progressing through development and commercialization. For example, companies invest in monoclonal antibodies and recombinant proteins for oncology, autoimmune diseases, and other therapeutic areas. A broader development pipeline increases future availability of biologic products and strengthens production capacity. Continued investment therefore supports expansion of the biologics market.
Limited Access to Advanced Manufacturing Infrastructure and Complex Manufacturing and Production Processes Restrain Market Expansion
Limited access to specialized bioreactors, sterile processing systems, and advanced quality-control facilities can restrict biologics production capacity. High infrastructure costs and technical requirements can make facility development difficult, particularly for smaller manufacturers and emerging markets. These constraints can delay production scale-up and limit broader market expansion.
Biologics require controlled production conditions, multiple processing stages, and strict quality checks to maintain product consistency and safety. Process complexity can increase manufacturing time, operational costs, and the risk of batch variability or production failure. These challenges can limit scalability and slow the adoption of biologic therapies.
Biologics for Veterinary Therapeutics and Development of Oral and Alternative-Route Biologics Offer Growth Opportunities
Veterinary pharmaceutical companies, animal-health providers, and biologics developers can target biologic therapies for companion animals and livestock. Companies such as Zoetis can expand revenue through specialized biologic products for animal diseases, creating an additional market beyond human therapeutics.
Biopharmaceutical companies and drug-delivery technology providers can develop oral, inhaled, nasal, and other non-injectable biologic formats. Companies such as Oramed Pharmaceuticals are developing oral delivery technologies, creating opportunities for licensing, formulation partnerships, and new product commercialization.
Supply Disruptions for Critical Biologic Inputs and Cold-Chain and Storage Requirements Hinder Growth
Dependence on specialized cell-culture media, resins, filters, single-use components, and other inputs can expose manufacturers to supply interruptions. Shortages of single-use bioprocessing components have previously affected biopharmaceutical manufacturers, highlighting how supplier disruptions can delay production and limit reliable product availability.
Biologics often require controlled temperature conditions throughout manufacturing, transportation, and storage, increasing logistics complexity and limiting distribution in regions with unreliable cold-chain infrastructure. For example, temperature excursions during vaccine transportation can compromise product quality, leading to product losses and restricting access in markets with weak cold-chain networks.
The mammalian segment accounted for a share of 71% in 2025 and is expected to grow at a CAGR of 8.1% during the forecast period 2026-2034, owing to the established use of mammalian cell systems for producing complex biologics, supported by their ability to facilitate appropriate protein folding and post-translational modifications. The microbial segment supports production of biologics that can be efficiently expressed through microbial systems.
Request Customizationto receive a tailored report.
The in-house segment accounted for a share of 66% in 2025, owing to the control it provides over manufacturing processes, quality standards, and production capacity. The outsourced segment enables companies to access specialized manufacturing capabilities and external production infrastructure.
The outsourced segment is expected to grow at a CAGR of 8.6% during the forecast period 2026-2034, driven by increasing demand for specialized manufacturing capabilities, flexible production capacity, and access to external bioprocessing expertise. The in-house segment continues to support companies maintaining direct control over biologics manufacturing.
The monoclonal antibodies segment accounted for a share of 45% in 2025, owing to their extensive use across oncology, immunological disorders, and other therapeutic areas. The vaccines segment supports prevention of infectious diseases, while the recombinant proteins segment includes therapeutics produced through recombinant biological systems. The antisense & RNAi therapeutics segment enables targeted modulation of gene expression, and the others segment includes additional biologic products.
The antisense & RNAi therapeutics segment is expected to grow at a CAGR of 9.5% during the forecast period 2026-2034, driven by increasing development of nucleic acid-based therapies and growing use of gene-expression modulation approaches. The monoclonal antibodies, vaccines, recombinant proteins, and other segments continue to support diverse therapeutic applications.
The oncology segment accounted for a share of 36% in 2025 and is expected to grow at a CAGR of 8.8% during the forecast period 2026-2034, owing to extensive use of biologics in cancer treatment, supported by continued development of targeted and immune-based therapies. The infectious diseases segment supports biologic applications in disease prevention and treatment, while the immunological disorders segment includes therapies targeting abnormal immune responses. The cardiovascular disorders segment supports treatment of cardiovascular conditions, the hematological disorders segment serves blood-related diseases, and the others segment includes additional disease categories.
The tumor necrosis factor (TNF) inhibitor segment accounted for a share of 28% in 2025, owing to its established use in treating inflammatory and immune-mediated disorders. The T-cell inhibitor segment modulates T-cell activity, while the selective co-stimulation modulators segment targets immune-cell signaling pathways. The interleukin-6 (IL-6) or interleukin-17 blocker segment addresses specific inflammatory pathways, the interleukin-1 (IL-1) blocker segment targets IL-1-mediated inflammation, and the B-cell inhibitor segment supports therapies targeting B-cell activity.
The interleukin-6 (IL-6) or interleukin-17 blocker segment is expected to grow at a CAGR of 8.5% during the forecast period 2026-2034, driven by increasing use of biologic therapies targeting specific inflammatory pathways. The TNF inhibitor, T-cell inhibitor, selective co-stimulation modulators, interleukin-1 blocker, and B-cell inhibitor segments continue to support treatment across immune-mediated conditions.
The mammalian segment accounted for a share of 67% in 2025 and is expected to grow at a CAGR of 8.1% during the forecast period 2026-2034, owing to its established role in producing complex biologics, supported by its suitability for proteins requiring mammalian-specific processing. The microbial segment supports biologic production through microbial expression systems, while the others segment includes additional source systems.
The prescription drugs segment accounted for a share of 91% in 2025 and is expected to grow at a CAGR of 7.9% during the forecast period 2026-2034, owing to the specialized nature of biologic therapies and their use under healthcare-provider supervision, supported by the need for clinical assessment and treatment monitoring. The over-the-counter (OTC) drugs segment covers biologic-related products available without prescription.
The hospitals segment accounted for a share of 48% in 2025, owing to their extensive oncology, specialty care, infusion, and diagnostic infrastructure for biologic treatment. The specialty clinics segment provides focused care for patients requiring biologic therapies, while the homecare segment supports administration and monitoring outside traditional healthcare facilities. The others segment includes additional healthcare settings.
The homecare segment is expected to grow at a CAGR of 9.1% during the forecast period 2026-2034, driven by increasing adoption of home-based treatment and the growing availability of biologic therapies suitable for administration outside hospitals. The hospitals and specialty clinics segments continue to support complex and specialized biologic treatment, while other end users serve additional care requirements.
The hospital pharmacy segment accounted for a share of 52% in 2025, owing to the high use of biologics within hospital-based treatment and the need for controlled dispensing and storage. The retail pharmacy segment supports community-based access to eligible biologic products, while the online pharmacy segment provides digital ordering and delivery channels. The other segment includes additional distribution channels.
The online pharmacy segment is expected to grow at a CAGR of 9.8% during the forecast period 2026-2034, driven by increasing adoption of digital healthcare services and greater use of online channels for medicine ordering and delivery. The hospital pharmacy and retail pharmacy segments continue to support established biologic distribution, while other channels serve additional purchasing requirements.
Speak to an Analystto discuss market opportunities.
The North America biologics market accounted for the largest regional share of 43% in 2025. The region’s position is supported by continued biologic innovation in the U.S., with the FDA reporting 18 new biosimilar approvals in 2025 and 81 biosimilars approved since 2015, expanding treatment options and competition in the biologics ecosystem. The FDA also identifies biologics as the fastest-growing class of medications in the United States, indicating continued demand for advanced biological therapies.
The United States biologics market is expected to benefit from streamlined biosimilar development, with the FDA estimating that its 2026 reforms could reduce biosimilar pharmacokinetic study costs by up to 50% (about $20 million), while biologics already accounted for 51% of total U.S. drug spending in 2024. The Canada biologics market is expected to be supported by an aging population, with Statistics Canada projecting the share of people aged 65 and over to rise from 18.9% in 2023 to as high as 32.3% by 2073, while the population aged 85 and over could increase from 896,600 to 3.3–4.3 million over the same period, increasing demand for treatments for age-related conditions.
Unlock Regional Insightsto access country-level data, & regional trends.
The European biologics market is expected to grow at a CAGR of 8.9% during 2026–2034, showcasing the fastest-growing regional market. The European Commission reported that biological medicines generated EUR 95 billion in sales in 2024, representing 41% of total pharmaceutical spending in the EU, while cumulative biosimilar authorizations are projected to increase from 151 in 2025 to 250–350 by 2030, supporting continued expansion of the biologics ecosystem.
The UK biologics market is expected to benefit from biosimilar adoption, with NHS England estimating that widespread uptake of biosimilars becoming available through 2028 could generate up to £1 billion in savings, creating scope for greater access and reinvestment in biological medicines. The Germany biologics market is expected to benefit from continued biopharmaceutical development, with Germany’s Federal Ministry of Health funding a biosimilar regulatory research project running through March 2029, while pharmacy-level substitution rules for biologic medicines took effect in April 2026, supporting broader use of lower-cost biological alternatives. The France biologics market is expected to be supported by France 2030, which targets the production of at least 20 biomedicines in France by 2030, alongside €2.3 billion in funding for biotherapies and bioproduction, strengthening domestic biologics development and manufacturing capacity.
The Asia Pacific biologics market accounted for a regional share of 20% in 2025. The region’s expanding healthcare needs and biopharmaceutical capacity are supported by population ageing, with the WHO projecting the number of people aged 65 and above in the Asia-Pacific region to nearly double from around 503 million currently to about 1 billion by 2050, increasing the need for treatments for age-related and chronic diseases.
The Japan biologics market is expected to benefit from government support for biopharmaceutical expansion, with the Cabinet Office targeting growth in the domestic biopharmaceutical and regenerative-medicine market from about ¥1.5 trillion in 2020 to more than ¥3.3 trillion by 2030, while the government aims for biosimilars to account for at least 60% of ingredients by the end of FY2029. The China biologics market is expected to be supported by the country’s 2026–2030 pharmaceutical plan, which targets at least 25% of global first-in-class drugs developed in China by 2030 and expects the innovative-drug sector to expand at an average annual rate of at least 20% during the plan period.The South Korea biologics market is expected to benefit from the government’s 2026–2030 advanced-regenerative-medicine plan, which targets at least 150 cumulative approvals for clinical research and treatment plans and at least five domestically developed advanced biopharmaceuticals by 2030, alongside expanded support for manufacturing automation and quality management. The India biologics market is expected to gain from the ₹10,000 crore Biopharma SHAKTI programme over five years, which aims to strengthen domestic biologics and biosimilars production and help India capture 5% of the global biopharmaceutical market, while the broader bioeconomy is targeted to reach $300 billion by 2030.
The biologics market is moderately fragmented, with participation from multinational pharmaceutical companies, biotechnology companies, specialty biologics manufacturers, contract development and manufacturing organizations, and regional biopharmaceutical firms. The leading players in the global biologics market are Bristol-Myers Squibb Company, Merck KGaA, Novartis AG, Novo Nordisk A/S, and Pfizer Inc., and a reliable cumulative market-share figure for these exact five companies is not publicly disclosed, so no verified combined percentage should be stated.
Established players compete primarily on clinical efficacy, product safety, research and development capabilities, manufacturing scale, regulatory expertise, product portfolios, intellectual property, and established healthcare-provider relationships. Emerging and regional players in the biologics market ecosystem compete through innovative biologic platforms, targeted therapies, biosimilars, specialized formulations, flexible manufacturing capabilities, cost-efficient production, and application-specific solutions.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Gene Therapy Cell Culture Media Market Size, Share, Growth, 2034
CRISPR-Cas9 Gene Editing Technologies Market Size, Share, 2034
Immunoprotein Diagnostic Testing Market Size, Share, Growth, 2034
Fertility Test Market Size, Share, Growth, Analysis, Report, 2034
Cell Culture Market Size, Share, Growth, Analysis, Report, 2034
Genome Editing Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com